Kevin (on behalf of Chris Shibutani)'s questions to Exelixis Inc (EXEL) leadership • Q4 2024
Question
Kevin, on for Chris Shibutani, asked about the early-stage pipeline, seeking details on the amount and cadence of data presentations expected this year and the go/no-go decision process for new INDs.
Answer
Chief Scientific Officer Dana Aftab advised to 'stay tuned' for abstract publications for specifics on data presentations. Regarding pipeline advancement, he described a standard, best-practices approach where assets proceed after passing all required bars in IND-enabling activities, such as GLP toxicology, to ensure a strong scientific hypothesis before entering the clinic.